Onco Actu du 17 mai 2017

	1. Biologie
Biology needs more staff scientists [Nature] Today, our work at the Broad would be unthinkable without professional staff scientists — biologists, chemists, data scientists, statisticians and engineers. These researchers are not pursuing a tenured academic post and do not supervise graduate students, but do cooperate on and lead projects that could not be accomplished by a single academic laboratory.
Jumping Genes and the Dark Genome: MSK Researchers Gain New Insight into Childhood Cancers [Memorial SLoan kettering Cancer Center] Researchers have found that a gene called PGBD5 plays a role in causing many pediatric cancers by creating mutations that turn cells malignant.
	4.2 Dép., diag. & prono. - Génome
Do Genomic Approaches to Selecting Cancer Treatment Yield Better Patient Outcomes Than Traditional Approaches? [Cancer Research Catalyst] A study published recently in the AACR’s journal Cancer Discovery addresses the burgeoning question of the utility of high-throughput genomic analysis in identifying targeted therapies and delivering better outcomes for cancer patients, and adds important evidence to argue in favor of such an approach. The jury, nevertheless, is still out.
	5. Traitements
Potent targeted cancer drug shows promise in first patient trials [Institute of Cancer Research] The results show that talazoparib could benefit patients in the clinic – particularly women with BRCA-mutated breast and ovarian cancer.
Conjugate drug extends survival in patients with advanced HER2-positive breast cancer, trial shows [Dana-Farber Cancer Institute] The trial, known as the TH3RESA trial, enrolled 602 patients at 146 treatment centers in 22 countries. They were randomly assigned to be treated with either trastuzumab emtansine (T-DM1) or a treatment of their physician’s choice.
	5.2 Pharma
Bayer Receives FDA Priority Review For Investigational Anti-Cancer Compound Copanlisib [Bayer] Regulatory submission based on data from the Phase II CHRONOS-1 study, in which copanlisib showed objective response rate of 59% and a manageable safety profile in patients with follicular lymphoma.
	5.2.3 Pharma - économie
European Commission targets Aspen over 1,500% price hikes [Pharmafile] The price hikes in question reached as much as 1,500%; the drug maker was accused of blackmailing the Italian Medicines Agency in October last year by threatening to withhold its live-saving cancer drugs in various member states if its price hikes were not accepted. This behaviour was met with a €5 million fine from the Italian regulator.
Cancer drug price hike company investigated [BBC News] The European Commission has launched an investigation into claims that drug company Aspen Pharma excessively increased prices of five life-saving cancer medicines. The drugs include chlorambucil and busulfan - used to treat leukaemia.
	5.4 Traitements - Economie
Gottlieb tells staffers FDA can help—indirectly—to cut medicine prices [FierceBiotech] "We also need to take steps to make sure the generic drug process isn't being inappropriately gamed to delay competition and disadvantage consumers," said Gottlieb, adding: "I hope to have much more to say on this topic in the coming weeks."
	6. Lutte contre les cancers
Counseling Improves Survivorship Plan Implementation for Low-Income Breast Cancer Survivors [NCI] In this NCI-supported trial, doctors caring for low-income, predominantly Latina breast cancer survivors who had undergone a nurse-led educational session on their care plan were much more likely to address issues such as depression and hot flashes than the doctors of survivors who didn't receive the counseling.
	6.7 DMP, Big Data & applis
Google DeepMind patient app legality questioned [BBC News] The head of the Department of Health's National Data Guardian (NDG) has criticised the NHS for the deal it struck with Google's DeepMind over sharing patient data.